| Original language | English (US) |
|---|---|
| Pages (from-to) | 1315-1362 |
| Number of pages | 48 |
| Journal | Journal of Clinical Psychiatry |
| Volume | 78 |
| Issue number | 9 |
| DOIs | |
| State | Published - Nov 1 2017 |
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Clinical Psychiatry, Vol. 78, No. 9, 01.11.2017, p. 1315-1362.
Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Utilizing y g the DSM-5 anxious y distress specifier to develop treatment strategies for patients with major depressive disorder
AU - Thase, Michael E.
AU - Weisler, Richard H.
AU - Manning, J. Sloan
AU - Trivedi, Madhukar H.
N1 - Funding Information: This evidence-based peer-reviewed AcAdemic HigHligHts was prepared by Healthcare Global Village, Inc. Financial support for preparation and dissemination of this AcAdemic HigHligHts was provided by Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck, Inc. The faculty acknowledges Sarah Brownd, MA, for editorial assistance in developing the manuscript. The opinions expressed herein are those of the faculty and do not necessarily reflect the views of Healthcare Global Village, Inc, the publisher, or the commercial supporters. This article is distributed by Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck, Inc., for educational purposes only. Funding Information: consultant for Acadia, Alkermes, Allergan (Forest, Naurex), AstraZeneca, Cerecor, Eli Lilly, Fabre-Kramer, Gerson Lehrman Group, Guidepoint Global, Johnson & Johnson, (Janssen, Ortho-McNeil), Lundbeck, MedAvante, Merck, Moksha8, Nestlé (PamLab), Novartis, Otsuka, Pfizer, Shire, Sunovion, and Takeda; has received grant support from Agency for Healthcare Research and Quality, Alkermes, AssureRx, Avanir, Forest, Janssen, Intracellular, National Institute of Mental Health, Otsuka, and Takeda; has equity holdings in MedAvante; and has received royalties from American Psychiatric Foundation, Guilford Publications, Herald House, and W. W. Norton & Company. Dr Thase’s spouse is employed by Peloton Advantage. Dr Manning has been a consultant for and served on speakers/advisory boards for Otsuka, Takeda, Lundbeck, Alkermes, and Sunovion. Dr Weisler has been a consultant to Alcobra, AltheaDx, lronshore, Lundbeck, Major League Baseball (certified MLB clinician [therapeutic use exemption]), National Football League (certified NFL clinician [therapeutic use exemption]), Neos Therapeutics, Nestlé Health Science-PamLab, Otsuka America, Rhodes, Shire, Sunovion, Supernus, and Validus; served on the speakers bureaus of Lundbeck, Neos Therapeutics, Nestlé Health Science-PamLab, Otsuka America, Rhodes, Shire, Sunovion, and Validus; and received research support from Alcobra, Allergan, Daiichi Sankyo, Genomind, Janssen, Merck, Neurim, Otsuka America, Roche-Genentech, Shire, Suven Life Sciences, and Theravance. Dr Trivedi has been a consultant to Alkermes, Allergan, Acadia, AstraZeneca, Bristol-Myers Squibb, Cerecor, Global Medical Education, Health Research Assoc, Lundbeck, Medscape, MSI Methylation Services, Merck, Naurex, Nestlé Health Science-PamLab, One Carbon Therapeutics, Otsuka America, PamLab, Pfizer, Roche, Shire Development, and Takeda; received grant/research support from National Institute of Mental Health, National Institute on Drug Abuse, Johnson & Johnson, and Janssen R&D; and received other financial/material support from Janssen R&D.
PY - 2017/11/1
Y1 - 2017/11/1
UR - http://www.scopus.com/inward/record.url?scp=85040061195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040061195&partnerID=8YFLogxK
U2 - 10.4088/JCP.ot17015ah1
DO - 10.4088/JCP.ot17015ah1
M3 - Review article
C2 - 29188904
AN - SCOPUS:85040061195
SN - 0160-6689
VL - 78
SP - 1315
EP - 1362
JO - Journal of Clinical Psychiatry
JF - Journal of Clinical Psychiatry
IS - 9
ER -